ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Nov 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 9B. OTHER INFORMATION
(b)Trading Plans
During the fiscal quarter ended September 30, 2025, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):
| Name | Title | Adoption or Termination Date | Plan End Date | Shares Vesting and Subject to Sell-To-Cover (1) | Other Shares Being Sold (Subject to Certain Conditions) |
|---|---|---|---|---|---|
| Adeoye Olukotun | Board Member | 09/04/2025 | 12/24/2025 | n/a | 10,000 |
| Christopher Anzalone | President and Chief Executive Officer | 09/19/2025 | 12/24/2026 | 50,000 | n/a |
| Daniel Apel | Chief Financial Officer | 09/16/2025 | 04/30/2026 | 25,000 | n/a |
| James Hamilton | Chief Medical Officer, Head of R&D | 09/03/2025 | 01/16/2026 | 72,500 | n/a |
| Mauro Ferrari | Board Member | 09/25/2025 | 12/31/2025 | n/a | 7,530 |
| Patrick O'Brien | Chief Operating Officer & General Counsel | 09/03/2025 | 01/07/2026 | 77,500 | 20,000 |
| Victoria Vakiener | Board Member | 09/03/2025 | 12/31/2025 | n/a | 10,040 |
| William Waddill | Board Member | 09/03/2025 | 12/31/2025 | n/a | 8,367 |
(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.